Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru.

摘要: Author(s): Forshey, Brett M; Reiner, Robert C; Olkowski, Sandra; Morrison, Amy Espinoza, Angelica; Long, Kanya Vilcarromero, Stalin; Casanova, Wilma; Wearing, Helen J; Halsey, Eric S; Kochel, Tadeusz Scott, Thomas W; Stoddard, Steven T | Abstract: BackgroundNearly half of the world's population is at risk for dengue, yet no licensed vaccine or anti-viral drug currently available. Dengue caused by any four dengue virus serotypes (DENV-1 through DENV-4), and infection a DENV serotype assumed to provide life-long protection against re-infection that serotype. We investigated validity this fundamental assumption during large epidemic DENV-2 in Iquitos, Peru, 2010-2011, 15 years after first outbreak region.Methodology/principal findingsWe estimated age-dependent prevalence serotype-specific antibodies from longitudinal cohort studies conducted between 1993 2010. During 2010-2011 epidemic, active cases were identified community- clinic-based febrile surveillance studies, acute inapparent infections contact tracing studies. Based on age-specific neutralizing antibodies, age distribution was markedly older than expected. Homologous 35.1% (95% confidence interval: 0%-65.2%). At individual level, pre-existing associated with an incomplete reduction frequency symptoms. Among cases, 43% (26/66) exhibited elevated antibody titers prior infection, compared 76% (13/17) (age-adjusted odds ratio: 4.2; 95% 1.1-17.7).Conclusions/significanceOur data indicate homologous may be some circumstances, which provides context limited efficacy recent trials. Further are warranted confirm phenomenon evaluate potential role transmission dynamics.